{"success":true,"data":{"pressRelease":{"id":"32237","rtpr_id":"nBw6fmdfMa","ticker":"CTNM","exchange":"NASDAQ","all_tickers":["CTNM"],"title":"Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference","author":"Business Wire","published_at":"2026-05-12T20:05:00.160Z","article_body":"Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global\nHealthcare Conference\n\nContineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a\nclinical-stage biopharmaceutical company pioneering differentiated therapies\nfor the treatment of neuroscience, inflammation and immunology (NI&I)\nindications, today announced that management is scheduled to present at the\n2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at\n3:35 p.m. ET.\n\nAn audio webcast of the fireside chat can be accessed on the Investors\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.contineum-tx.com%2F&esheet=54529549&newsitemid=20260512847258&lan=en-US&anchor=Investors&index=1&md5=e1c71dcd7defb044f5f605f871e725de)\nsection of Contineum’s website. A webcast replay will also be available.\n\nAbout Contineum Therapeutics\n\nContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical\ncompany pioneering novel, oral small molecule therapies for NI&I\nindications with significant unmet need. Contineum is advancing a pipeline of\ninternally-developed programs with multiple drug candidates now in clinical\ntrials. PIPE-791 is an LPA1 receptor antagonist in clinical development for\nidiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective\ninhibitor of the M1 receptor in clinical development for relapsing-remitting\nmultiple sclerosis and major depressive disorder. For more information, please\nvisit www.contineum-tx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.contineum-tx.com&esheet=54529549&newsitemid=20260512847258&lan=en-US&anchor=www.contineum-tx.com&index=2&md5=a222d979f049fc3ceca506211a5cff7c)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260512847258/en/\n(https://www.businesswire.com/news/home/20260512847258/en/)\n\nSteve Kunszabo\n\nContineum Therapeutics\n\nSenior Director, Investor Relations & Corporate Communications\n\n858-649-1158\n\nskunszabo@contineum-tx.com (mailto:skunszabo@contineum-tx.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6fmdfMa","title":"Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference","author":"Business Wire","ticker":"CTNM","created":"2026-05-12T20:05:00.160Z","tickers":["CTNM"],"exchange":"NASDAQ","article_body":"Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global\nHealthcare Conference\n\nContineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a\nclinical-stage biopharmaceutical company pioneering differentiated therapies\nfor the treatment of neuroscience, inflammation and immunology (NI&I)\nindications, today announced that management is scheduled to present at the\n2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at\n3:35 p.m. ET.\n\nAn audio webcast of the fireside chat can be accessed on the Investors\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.contineum-tx.com%2F&esheet=54529549&newsitemid=20260512847258&lan=en-US&anchor=Investors&index=1&md5=e1c71dcd7defb044f5f605f871e725de)\nsection of Contineum’s website. A webcast replay will also be available.\n\nAbout Contineum Therapeutics\n\nContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical\ncompany pioneering novel, oral small molecule therapies for NI&I\nindications with significant unmet need. Contineum is advancing a pipeline of\ninternally-developed programs with multiple drug candidates now in clinical\ntrials. PIPE-791 is an LPA1 receptor antagonist in clinical development for\nidiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective\ninhibitor of the M1 receptor in clinical development for relapsing-remitting\nmultiple sclerosis and major depressive disorder. For more information, please\nvisit www.contineum-tx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.contineum-tx.com&esheet=54529549&newsitemid=20260512847258&lan=en-US&anchor=www.contineum-tx.com&index=2&md5=a222d979f049fc3ceca506211a5cff7c)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260512847258/en/\n(https://www.businesswire.com/news/home/20260512847258/en/)\n\nSteve Kunszabo\n\nContineum Therapeutics\n\nSenior Director, Investor Relations & Corporate Communications\n\n858-649-1158\n\nskunszabo@contineum-tx.com (mailto:skunszabo@contineum-tx.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-12T20:05:00.205432981Z","server_sent_at_ms":1778616300205},"received_at":"2026-05-12T20:05:00.343Z","source_url":"https://www.businesswire.com/news/home/20260512847258/en/"},"analysis":{"id":"23321","press_release_id":"32237","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Contineum Therapeutics announced that management will present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th.\n\nThe fireside chat will be webcast and available for replay on the company's investor relations website.\n\nContineum is a clinical-stage biopharmaceutical company focused on oral small molecule therapies for neuroscience, inflammation and immunology indications.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference presentation."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Steve Kunszabo","role":"Senior Director, Investor Relations & Corporate Communications"}],"products":["PIPE-791","PIPE-307"],"companies":[{"name":"Contineum Therapeutics, Inc.","ticker":"CTNM"},{"name":"RBC Capital Markets","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference presentation announcement with no material disclosures or updates to business operations."},"tickerRelevance":{"others":[],"primary":"CTNM"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-attendance","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Contineum Therapeutics announced that management will present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th.\n\nThe fireside chat will be webcast and available for replay on the company's investor relations website.\n\nContineum is a clinical-stage biopharmaceutical company focused on oral small molecule therapies for neuroscience, inflammation and immunology indications.","key_figures":null,"named_entities":{"people":[{"name":"Steve Kunszabo","role":"Senior Director, Investor Relations & Corporate Communications"}],"products":["PIPE-791","PIPE-307"],"companies":[{"name":"Contineum Therapeutics, Inc.","ticker":"CTNM"},{"name":"RBC Capital Markets","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a68c0d5c02b24190","schema_hash":"sha256:4b22e0a142e5d4b1","created_at":"2026-05-12T20:09:03.460Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-attendance","sectorWeight":"biotech"}},"durationMs":241304,"modelName":"george-droid-qwen-72b"}}